Predict your next investment

Venture Capital
eastoncapital.com

See what CB Insights has to offer

Investments

121

Portfolio Exits

25

Funds

7

Service Providers

1

About Easton Capital

Easton Capital is a Venture Capital Fund with a sector focus in healthcare and life sciences. Its professionals have decades of experience in all aspects of healthcare, providing unique financial, strategic, operational perspectives and resources to entrepreneurs who want to grow their business.

Easton Capital Headquarter Location

767 Third Avenue 7th Floor

New York, New York, 10017,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Easton Capital News

Claret Medical Closes $14.5 Million in Series C Financing to Extend Successful U.S. Launch of Sentinel Cerebral Protection System

Oct 24, 2017

Claret Medical Closes $14.5 Million in Series C Financing to Extend Successful U.S. Launch of Sentinel Cerebral Protection System SANTA ROSA, Calif., October 23, 2017-- Claret Medical®, developer of the Sentinel® Cerebral Protection System, the first FDA-cleared cerebral protection device for transcatheter aortic valve replacement (TAVR), today announced that it has closed on a Series C financing of $14.5 million led by Lightstone Ventures, with participation from existing investors Easton Capital, HealthCor Partners, Incept LLC and Sante Ventures. As the leader in cerebral protection for TAVR, the company will use the proceeds to support market access programs, research and development for next generation products, and expansion of the commercial organization to build upon the successful controlled commercial release of the company’s Sentinel Cerebral Protection System in the U.S. Since the company’s Series B round in 2014, Claret Medical has pursued a structured study program of the Sentinel device involving three randomized studies and more than 2,300 patients, including its U.S. SENTINEL pivotal trial and a large-scale, real-world trial. It has also gained FDA clearance and successfully commercialized Sentinel in leading TAVR centers across Europe, selected Asia Pacific countries and, most recently, the U.S. To date, more than 5,000 patients have benefited from the use of Claret Medical’s cerebral protection technology during their cardiovascular procedures. “We appreciate our investors’ continued confidence in the large market opportunity presented by our technology,” said Claret Medical CEO Azin Parhizgar, PhD. “Our ongoing investment in a broad clinical program has shown that Sentinel is safe, easy to use and highly effective in reducing periprocedural TAVR stroke by 70 percent.1 We look forward to continuing to work with leading TAVR centers around the country to integrate Protected TAVR using the Sentinel into their programs to enhance patient safety.” Sentinel is the first and only FDA-cleared device that captures and removes debris that is dislodged ubiquitously during TAVR, regardless of the TAVR system used or a patient’s risk profile, before it can travel to the brain and potentially cause neurological and neurocognitive damage. About Claret Medical A privately-held company, Claret Medical develops innovative solutions for cerebral protection during structural heart and vascular interventions. Believing that not all cerebral protection devices are created equal, the company developed the Sentinel dual-filter system as the only system to capture and remove debris from the patient. It has been the leader in the field of cerebral protection since 2011 and is currently the only commercialized cerebral protection device available in Europe. It is also the first and only commercially available cerebral protection in the U.S for Protected TAVR. For more information on Sentinel or the Company, please visit www.claretmedical.com. 1. Seeger J, Gonska B, Otto M, Rottbauer W, Wöhrle J. Cerebral embolic protection during transfemoral aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv. 2017 Sep 7. pii: S1936-8798(17)31313-4. doi: 10.1016/j.jcin.2017.06.037. [Epub ahead of print] Contact:

Easton Capital Investments

121 Investments

Easton Capital has made 121 investments. Their latest investment was in Precise Light Surgical as part of their Unattributed VC on June 6, 2020.

CBI Logo

Easton Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/21/2020

Unattributed VC

Precise Light Surgical

$0.02M

No

1

5/27/2020

Series C - II

Bright.MD

$8.66M

No

2

3/20/2020

Series C

Bright.MD

$8.07M

Yes

11

6/18/2019

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

3/13/2019

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/21/2020

5/27/2020

3/20/2020

6/18/2019

3/13/2019

Round

Unattributed VC

Series C - II

Series C

Unattributed VC

Unattributed

Company

Precise Light Surgical

Bright.MD

Bright.MD

Subscribe to see more

Subscribe to see more

Amount

$0.02M

$8.66M

$8.07M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

11

10

10

Easton Capital Portfolio Exits

25 Portfolio Exits

Easton Capital has 25 portfolio exits. Their latest portfolio exit was Promedior on November 15, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/15/2019

Acquired

$99M

4

3/13/2019

Acquired

1

7/20/2018

Acquired

$99M

2

6/22/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/2/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/15/2019

3/13/2019

7/20/2018

6/22/2018

6/2/2014

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Easton Capital Acquisitions

3 Acquisitions

Easton Capital acquired 3 companies. Their latest acquisition was DDF Skincare on January 12, 2007.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/12/2007

$99M

Acquired

1

7/15/2006

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

0

12/6/2004

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/12/2007

7/15/2006

12/6/2004

Investment Stage

Series D

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

0

0

Easton Capital Fund History

7 Fund Histories

Easton Capital has 7 funds, including Easton Special Situations Fund II LLC.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/21/2014

Easton Special Situations Fund II LLC

Early-Stage Venture Capital

Open

$10M

1

12/17/2012

Easton Special Situations Fund LLC

Subscribe to see more

Subscribe to see more

10

3/31/2010

Easton Capital Partners II LP

Subscribe to see more

Subscribe to see more

10

12/31/2006

Easton Capital Partners

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2003

Easton Hunt New York LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/21/2014

12/17/2012

3/31/2010

12/31/2006

12/31/2003

Fund

Easton Special Situations Fund II LLC

Easton Special Situations Fund LLC

Easton Capital Partners II LP

Easton Capital Partners

Easton Hunt New York LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$10M

$99M

$99M

Sources

1

10

10

10

10

Easton Capital Service Providers

1 Service Provider

Easton Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Easton Capital Team

13 Team Members

Easton Capital has 13 team members, including current Founder, Managing Partner, John H. Friedman.

Name

Work History

Title

Status

John H. Friedman

Founder, Managing Partner

Current

Lawrence Kauvar

Founder

Current

Francisco A. Garcia

Managing Director

Current

Charles B. Hughes

Managing Director

Current

Richard Lipkin

Managing Director

Current

Name

John H. Friedman

Lawrence Kauvar

Francisco A. Garcia

Charles B. Hughes

Richard Lipkin

Work History

Title

Founder, Managing Partner

Founder

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.